Gan Lifeng, Zheng Liying, Zou Junrong, Luo Peiyue, Chen Tao, Zou Jun, Li Wei, Chen Qi, Cheng Le, Zhang Fangtao, Qian Biao
The First Clinical College, Gannan Medical University, Ganzhou, Jiangxi, China.
Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Front Cell Dev Biol. 2024 Jul 23;12:1437951. doi: 10.3389/fcell.2024.1437951. eCollection 2024.
The three most common kinds of urologic malignancies are prostate, bladder, and kidney cancer, which typically cause substantial morbidity and mortality. Early detection and effective treatment are essential due to their high fatality rates. As a result, there is an urgent need for innovative research to improve the clinical management of patients with urologic cancers. A type of small noncoding RNAs of 22 nucleotides, microRNAs (miRNAs) are well-known for their important roles in a variety of developmental processes. Among these, microRNA-21 (miR-21) stands out as a commonly studied miRNA with implications in tumorigenesis and cancer development, particularly in urological tumors. Recent research has shed light on the dysregulation of miR-21 in urological tumors, offering insights into its potential as a prognostic, diagnostic, and therapeutic tool. This review delves into the pathogenesis of miR-21 in prostate, bladder, and renal cancers, its utility as a cancer biomarker, and the therapeutic possibilities of targeting miR-21.
三种最常见的泌尿系统恶性肿瘤是前列腺癌、膀胱癌和肾癌，它们通常会导致严重的发病率和死亡率。由于其高死亡率，早期检测和有效治疗至关重要。因此，迫切需要开展创新性研究以改善泌尿系统癌症患者的临床管理。微小RNA（miRNA）是一类由22个核苷酸组成的小型非编码RNA，因其在多种发育过程中的重要作用而广为人知。其中，微小RNA-21（miR-21）作为一种经常被研究的miRNA脱颖而出，它在肿瘤发生和癌症发展中具有重要意义，尤其是在泌尿系统肿瘤中。最近的研究揭示了miR-21在泌尿系统肿瘤中的失调情况，为其作为预后、诊断和治疗工具的潜力提供了见解。本综述深入探讨了miR-21在前列腺癌、膀胱癌和肾癌中的发病机制、作为癌症生物标志物的效用以及靶向miR-21的治疗可能性。
